Curanex Pharmaceuticals (NASDAQ:CURX) Trading Up 21.8% – Should You Buy?

Curanex Pharmaceuticals Inc (NASDAQ:CURX) shares rose 21.8% on Wednesday . The stock traded as high as $0.2820 and last traded at $0.2704. 1,789,116 shares changed hands during trading, an increase of 1,193% from the average daily volume of 138,394 shares. The stock had previously closed at $0.2220.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Stock Performance

The business has a fifty day simple moving average of $4.68 and a 200 day simple moving average of $6.60. The stock has a market cap of $147.71 million and a price-to-earnings ratio of -12.08.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings results on Friday, August 14th. The company reported ($2.40) earnings per share for the quarter.

Institutional Investors Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.